COVID-19 and the Use of Immunomodulatory Agents in Ophthalmology

Degirmenci M. F. K., YALÇINDAĞ F. N., Tugal-Tutkun I.

TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, cilt.51, sa.4, ss.231-242, 2021 (ESCI) identifier identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 51 Sayı: 4
  • Basım Tarihi: 2021
  • Doi Numarası: 10.4274/tjo.galenos.2021.68252
  • Dergi Adı: TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.231-242
  • Anahtar Kelimeler: COVID-19, immunomodulatory therapy, immunosuppressive, non-infectious uveitis, SARS-CoV-2, JUVENILE IDIOPATHIC ARTHRITIS, LONG-TERM SAFETY, MYCOPHENOLATE-MOFETIL, RHEUMATOID-ARTHRITIS, PSORIATIC-ARTHRITIS, REFRACTORY UVEITIS, EVOLVING CONSENSUS, DISEASE PATIENTS, BEHCETS-DISEASE, CROHNS-DISEASE
  • İstanbul Üniversitesi Adresli: Evet

Özet

Immunomodulatory agents are often used in the systemic treatment of non-infectious uveitis. These drugs consist of corticosteroids, conventional immunosuppressives, and biological agents. As it is known that they suppress the immune system, the most important concern associated with immunomodulatory therapy (IMT) is the increased risk of infection. The World Health Organization declared COVID-19 a pandemic on 11 March 2020. Although severe acute respiratory distress syndrome secondary to SARS-CoV-2 infection may develop in all people, patients who receive IMT may be at higher risk in terms of both the transmission of the infection and more severe disease course. Therefore, guidelines on the management of patients receiving IMT due to uveitis during the pandemic are needed. In this review, we examined the immunomodulatory drugs used in the treatment of uveitis in terms of infectious complications and the data of patients who received IMT during the COVID-19 pandemic and discussed recommendations for the use of these drugs. According to the latest information, patients who receive IMT may continue their treatment as long as there are no disruptions in regular complete blood count (especially white blood cell count >4,000/mu L) and liver and kidney function tests. Patients diagnosed with COVID-19 should be managed with a multidisciplinary approach.